Teacher Retirement System of Texas Takes $103,000 Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)

Teacher Retirement System of Texas acquired a new position in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 10,937 shares of the biopharmaceutical company’s stock, valued at approximately $103,000.

Other hedge funds have also modified their holdings of the company. Quantbot Technologies LP purchased a new position in Theravance Biopharma during the third quarter worth approximately $60,000. BNP Paribas Financial Markets increased its holdings in shares of Theravance Biopharma by 88.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 305,480 shares of the biopharmaceutical company’s stock worth $2,462,000 after buying an additional 143,781 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Theravance Biopharma by 29.1% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,978 shares of the biopharmaceutical company’s stock worth $137,000 after buying an additional 3,827 shares during the period. Martingale Asset Management L P boosted its holdings in Theravance Biopharma by 14.4% in the third quarter. Martingale Asset Management L P now owns 54,450 shares of the biopharmaceutical company’s stock valued at $439,000 after acquiring an additional 6,870 shares during the last quarter. Finally, Jane Street Group LLC grew its position in Theravance Biopharma by 1.1% during the third quarter. Jane Street Group LLC now owns 144,575 shares of the biopharmaceutical company’s stock valued at $1,165,000 after acquiring an additional 1,640 shares during the period. 99.10% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, SVP Rhonda Farnum sold 4,000 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $9.00, for a total value of $36,000.00. Following the sale, the senior vice president now owns 309,565 shares in the company, valued at approximately $2,786,085. This represents a 1.28 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 6.90% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Theravance Biopharma in a report on Tuesday, February 25th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $13.75.

Theravance Biopharma Trading Down 0.1 %

NASDAQ TBPH opened at $9.01 on Thursday. The stock has a market cap of $445.73 million, a P/E ratio of -8.92 and a beta of 0.14. The company’s fifty day simple moving average is $9.40 and its 200-day simple moving average is $9.12. Theravance Biopharma, Inc. has a 52 week low of $7.44 and a 52 week high of $10.90.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.26). The firm had revenue of $18.75 million for the quarter, compared to analysts’ expectations of $29.90 million. Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. On average, research analysts expect that Theravance Biopharma, Inc. will post -1.09 EPS for the current fiscal year.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.